Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
51
DARE Quote, Financials, Valuation and Earnings
Last price:
$2.16
Seasonality move
:
14.92%
Day range:
$2.10 - $2.18
52-week range:
$1.61 - $9.19
Dividend yield:
0%
P/E ratio:
95.38x
P/S ratio:
438.05x
P/B ratio:
10.85x
Volume:
94K
Avg. volume:
233.9K
1-year change:
-32.19%
Market cap:
$31M
Revenue:
$9.8K
EPS (TTM):
-$1.78
Analysts' Opinion
-
Consensus RatingDaré Bioscience, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.75, Daré Bioscience, Inc. has an estimated upside of 395.39% from its current price of $2.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $2.17.
Fair Value
-
According to the consensus of 3 analysts, Daré Bioscience, Inc. has 395.39% upside to fair value with a price target of $10.75 per share.
DARE vs. S&P 500
-
Over the past 5 trading days, Daré Bioscience, Inc. has underperformed the S&P 500 by -10.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Daré Bioscience, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Daré Bioscience, Inc. revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Daré Bioscience, Inc. reported revenues of $2.3K.
Earnings Growth
-
Daré Bioscience, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Daré Bioscience, Inc. reported earnings per share of -$0.28.
Enterprise value:
16.1M
EV / Invested capital:
1.46x
Price / LTM sales:
438.05x
EV / EBIT:
--
EV / Revenue:
333.94x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-0.94x
Price / Operating cash flow:
2.85x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.4M
Return On Assets:
-80.09%
Net Income Margin (TTM):
-34564.52%
Return On Equity:
--
Return On Invested Capital:
-459.12%
Operating Margin:
-159656.52%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $1M | $1.9M | $48.2K | $41.7K | $2.3K | |
| Gross Profit | $972.8K | $1.8M | -$1.4M | $31.9K | -$610.6K | |
| Operating Income | -$41.9M | -$23.1M | -$16.7M | -$4.7M | -$3.7M | |
| EBITDA | -$41.9M | -$23.1M | -$15.2M | -$4.6M | -$3.1M | |
| Diluted EPS | -$5.69 | -$0.44 | -$1.78 | -$0.55 | -$0.28 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $48.2M | $49.6M | $22.4M | $14.9M | $25M | |
| Total Assets | $48.8M | $50.4M | $25.1M | $18.1M | $30.7M | |
| Current Liabilities | $15.9M | $22.8M | $26.3M | $13.2M | $21.2M | |
| Total Liabilities | $16.9M | $24M | $27.3M | $19.5M | $27.9M | |
| Total Equity | $31.9M | $26.3M | -$2.3M | -$1.5M | $2.9M | |
| Total Debt | $15.8K | $194.6K | -- | $5.4M | $7.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$36.6M | -$8M | -$17.3M | -$5.9M | -$442.1K | |
| Cash From Investing | -$24.8K | -$617.5K | $103.7K | $282.3K | -$174.7K | |
| Cash From Financing | $10.3M | $5.9M | $19.3M | $436.4K | $18.7M | |
| Free Cash Flow | -$36.6M | -$8.6M | -$17.2M | -$5.6M | -$616.8K | |
DARE
Sector
Market Cap
$31M
$28M
Price % of 52-Week High
23.61%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-68.83%
-1.54%
1-Year Price Total Return
-32.19%
-17.48%
Beta (5-Year)
0.771
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.22
200-day SMA
Sell
Level
$2.43
Bollinger Bands (100)
Buy
Level
1.86 - 2.2
Chaikin Money Flow
Sell
Level
-110.9M
20-day SMA
Buy
Level
$2.02
Relative Strength Index (RSI14)
Buy
Level
56.00
ADX Line
Buy
Level
26.45
Williams %R
Neutral
Level
-47.4359
50-day SMA
Buy
Level
$1.96
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
130.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-14.1823)
Sell
CA Score
(Annual)
Level (-8.7848)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (11.1916)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley on November 28, 2005 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, DARE has received 3 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DARE average analyst price target in the past 3 months is $10.75.
-
Where Will Daré Bioscience, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Daré Bioscience, Inc. share price will rise to $10.75 per share over the next 12 months.
-
What Do Analysts Say About Daré Bioscience, Inc.?
Analysts are divided on their view about Daré Bioscience, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Daré Bioscience, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Daré Bioscience, Inc.'s Price Target?
The price target for Daré Bioscience, Inc. over the next 1-year time period is forecast to be $10.75 according to 3 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DARE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Daré Bioscience, Inc. is a Buy. 3 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DARE?
You can purchase shares of Daré Bioscience, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Daré Bioscience, Inc. shares.
-
What Is The Daré Bioscience, Inc. Share Price Today?
Daré Bioscience, Inc. was last trading at $2.16 per share. This represents the most recent stock quote for Daré Bioscience, Inc.. Yesterday, Daré Bioscience, Inc. closed at $2.17 per share.
-
How To Buy Daré Bioscience, Inc. Stock Online?
In order to purchase Daré Bioscience, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DARE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DARE
Sector
P/E ratio
95.38x
23.89x
PEG ratio
-0.02x
-0.01x
P/B ratio
10.85x
1.82x
Price / LTM sales
438.05x
1.60x
Growth Metrics
DARE
Sector
Revenue growth
-89.92%
4.62%
Earnings growth
-118.34%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.40
-$0.21
Profitability
DARE
Sector
Profitability FY 2024
-$503.5K
$3.5M
Return on invested capital
-459.12%
-31.77%
Return on assets
-80.09%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
30
Estimated Next Earnings Date
Feb
12
Balance Sheet
DARE
Sector
Total cash
$23.1M
$26.3M
Short term investments
--
$25.7M
Total assets
$22.1M
$78M
Long term debt
$7.6M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
